The disclosure relates to systems and devices for diagnosing infectious disease (e.g., bacterial or viral infections). More particularly, the disclosure relates to acoustic sensors for detecting infectious disease caused by viral infections (e.g., coronavirus, rhinovirus, influenza, etc.).

A solid support for detecting the presence of antibodies in a biological sample, where the solid support includes microbial antigens immobilized on the solid support, wherein the microbial antigens include at least one antigen prepared from the group consisting of pleomorphic round bodies of Borrelia genus, for example Borrelia burgdorferi, Borrelia afzelii and Borrelia garinii. Also, a method of detecting a tick-borne microbe in a biological sample, wherein the solid support is contacted with a biological sample.

Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides. Also disclosed are methods for predicting elimination of LD spirochetes in LD patients who have undergone LD treatment, by exposing whole blood samples from such subjects to peptides comprising specific T-cell epitope regions of Borrelia proteins that are expressed at different stages of Lyme disease, and confirming a lack of Borrelia-specific activated T-cells in the samples by the absence of a detectable T-cell immune response indicator (e.g., interferon-Y).

The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.

Compositions and methods are provided for diagnosis of infections. The patterns of antibody isotype, subtype and glycosylation provide for a signature pattern that can identify infective agents and patient response to infection. Patients likely to benefit from therapeutic intervention can be discriminated from patients that have a low probability of responsiveness. Therapies are also provided.

Provided herein are, inter alia, methods and kits for diagnosing post-treatment Lyme disease syndrome (PTLDS) or Lyme disease in a subject.

The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1-SEQ ID NO:28 and/or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.

The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.

Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.

Methods are provided for treating a subject for an infection by a pathogen expressing a CD47-like mimic protein on its surface. In particular, the methods comprise administering an agent that reduces the binding of the CD47 mimic protein on the pathogen to SIRPα on a phagocytic cell, wherein the agent is administered at an effective dose for increasing phagocytosis of the pathogen

C